Items where authors include "Bliss, J.M."

Article

Sydes, M.R., Murray, M.L., Ahmed, S. et al. (25 more authors) (2024) Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials. Contemporary Clinical Trials, 141. 107514. ISSN 1551-7144

Ring, A. orcid.org/0000-0003-1230-2973, Kilburn, L.S. orcid.org/0000-0002-1987-7545, Pearson, A. orcid.org/0000-0002-5854-193X et al. (21 more authors) (2023) Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: Results from Cohort E of the plasmaMATCH trial (CRUK/15/010). Clinical Cancer Research, 29 (23). pp. 4751-4759. ISSN 1078-0432

Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 24 (12). pp. 1359-1374. ISSN 1470-2045

Coombes, R.C., Tovey, H., Kilburn, L. et al. (230 more authors) (2021) Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer. JAMA Oncology, 7 (9). p. 1291. ISSN 2374-2437

Tutt, A., Tovey, H., Cheang, M.C.U. et al. (35 more authors) (2018) Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine, 24 (5). pp. 628-637. ISSN 1078-8956

Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045